Zeroing Out Drug Prices

As we head toward the end of the year, biopharmaceutical companies are announcing their pricing strategies for 2019.

Merck & Co. raised the list price of five drugs, including its blockbuster cancer treatment Keytruda, in November — raising the price of Keytruda by 1.5 percent and its human papillomavirus vaccine Gardasil by about 6 percent. The other three treatments that saw increases were vaccines. According to Merck, the average net price of their drugs declined 1.9 percent in 2017.

Under pressure from President Donald Trump, many drugmakers, including Pfizer, Roche and Novartis, agreed to freeze price hikes until the end of 2018. Pfizer’s announcement is particularly detailed and instructive. Here’s the headline of the company’s press release:

“Pfizer Provides Transparency on Drug Prices in the U.S. 90% of Company’s Prices Will Remain Unchanged”

When you separate the spin from the substance, here’s what the headline should be:

“Pfizer adjusts 2019 prices in order to achieve 0 percent net revenue growth”

That’s the truth — but it’s not likely to be reported (or tweeted by a certain someone) that way.

Here are the facts.



 
Sign Up for Our Email Newsletter

RECENT NEWS

Restoring the Balance Between Innovation and Generic Manufacturing of Medicines

Restoring the Balance Between Innovation and Generic Manufacturing of Medicines

Closing the patent challenge loophole is essential to restoring the balance between innovation and imitation. ...  Read more

How ‘Right to Try’ Laws Fail Patients Who Need Experimental Medicine

How ‘Right to Try’ Laws Fail Patients Who Need Experimental Medicine

The debate over access to experimental medicines must continue to evolve from Right to Try to the right way to try....  Read more

A front for government price controls

A front for government price controls

Let’s hope the measure doesn’t gain steam. Binding arbitration — essentially government price controls — would be catastr...  Read more

DRUGWONKS BLOG